Clinical & Genetic Studies in ALS and Other Neurodegenerative Motor Neuron Disorders

Mayo Clinic1 site in 1 country3,000 target enrollmentDecember 1, 2007

ConditionsAmyotrophic Lateral Sclerosis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Amyotrophic Lateral Sclerosis
Sponsor: Mayo Clinic
Enrollment: 3000
Locations: 1
Primary Endpoint: Blood Collection
Status: Recruiting
Last Updated: 8 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish a repository for future investigations of genetic contributions to ALS pathogenesis. Blood samples for DNA extraction also would be collected from control subjects with no personal or family history of ALS phenotypes.

Registry

clinicaltrials.gov

Start Date

December 1, 2007

End Date

December 1, 2038

Last Updated

8 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Mayo Clinic

Responsible Party

Principal Investigator

Bjorn E. Oskarsson

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•ALS or Suspected Patient • Limited mental capacity rendering the subject unable to provide written informed consent or assent or comply with standard phlebotomy procedures.
•Blood Relative of ALS Patient
•Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.
•Healthy Control Subject
•Personal or family history of dementia or other neurodegenerative disease (Parkinson disease, Alzheimer disease, etc.);
•Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.